
Did you know…
Screening for type 2 diabetes is often based on BMI alone.
There are a lot of risk factors other that can put you at risk of developing type 2 diabetes.
Screening for type 2 diabetes is often based on BMI alone.
There are a lot of risk factors other that can put you at risk of developing type 2 diabetes.
geneType™for Type 2 Diabetes is appropriate for:
geneType™ reports help you and your health provider translate your personal clinical, family and genetic data into an actionable preventable health plan.
key features of a geneType™ report:
Understand your baseline risk of developing type 2 diabetes.
Take risk-reducing steps that are personalised to your health.
To order online through our patient portal, follow these four simple steps to be connected with a third-party telehealth provider.
Register for your geneType™ test using our portal.
Depending on the test, you may require access to your medical records (ex. lipid panel or breast density results).
Payment will be collected at time of registration.
Your clinical information will be reviewed by our third party telehealth partner, DNA Visit.
If you qualify for testing, a kit will be shipped to your address on file.
If you do not qualify for testing, you will receive a refund.
Complete buccal sample collection as instructed and return in pre-paid envelope.
Do not eat, drink, smoke, vape or chew gum within 30 minutes of collection.
When your results are ready, you will have the chance to speak with your DNA Visit healthcare provider.
All at-risk patients will be required to speak with the provider prior to results-release.
If your question is not shown here, please Contact us directly.
Type 2 diabetes is a multifactorial disease and it is not possible to incorporate all potential risk factors into a risk prediction model.
This test is not applicable to adults who have fasting glucose levels above 126 mg/dL. In this case, the adult should undergo additional fasting blood glucose testing to confirm type 2 diabetes diagnosis. If an adult has pre-diabetes we can still risk assess them with a reading of 125 mg/dL or lower on our requisition.
No.
At this time geneType™ is a self-pay test. However, your patient may use FSA/HSA to pay for the test.
The benefit of geneType™ is in the common genetic markers that we examine and incorporate with other standard markers of risk, like cholesterol or fasting glucose levels. This gives you an advantage to visualize a component of your patient’s risk that you can’t see in traditional risk models. This leads to improved stratification, particularly in adults that may present with minimal clinical risk factors, but may have a high “baseline” risk based on these common genetic markers.
Importantly, lifestyle modifications are effective in reducing T2D risk across all genetic risk categories.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
Accredited For Compliance With NPAAC Standards And ISO 15189